SCHEMBL25855169

SCHEMBL25855169

C=C(C)CCc1ccc(NC(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.49
TDP1 Q9NUW8 3/20 0.41
ALDH1A1 P00352 5/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
CYP3A4 P08684 2/20 0.40
THRB P10828 2/20 0.40
ALOX15 P16050 2/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
ALOX12 P18054 1/20 0.40
RECQL P46063 1/20 0.40
ATM Q13315 1/20 0.40
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TP53 P04637 1/20 0.35
HSP90AA1 P07900 1/20 0.35
CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22694557 0.84 RXFP1 (0.44) RXFP1TDP1ALDH1A1L3MBTL1CYP3A4
SCHEMBL13282267 0.82 ALDH1A1 (0.53) RXFP1TDP1ALDH1A1L3MBTL1CYP3A4
SCHEMBL24920157 0.81 RXFP1 (0.51) RXFP1TDP1ALDH1A1L3MBTL1CYP3A4
SCHEMBL21706332 0.81 RXFP1 (0.41) RXFP1TDP1ALDH1A1L3MBTL1CYP3A4
SCHEMBL21566741 0.81 RXFP1 (0.41) RXFP1TDP1ALDH1A1L3MBTL1CYP3A4
SCHEMBL21569847 0.79 POLB (0.38) ALDH1A1CYP3A4THRBALOX15TSHR
SCHEMBL9911536 0.79 NPSR1 (0.58) ALDH1A1NPSR1FFAR1
SCHEMBL13254061 0.77 RXFP1 (0.44) RXFP1TDP1ALDH1A1L3MBTL1CYP3A4
SCHEMBL12871153 0.77 TDP1 (0.46) RXFP1TDP1ALDH1A1L3MBTL1CYP3A4
SCHEMBL28688598 0.76 SMN1; SMN2 (0.44) RXFP1ALDH1A1HSD17B10LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381321-A1 CAMPTOTHECIN CONJUGATES SEAGEN INC. 2023-11-30 US disclosed
WO-2023201234-A2 ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOF MINERVA BIOTECHNOLOGIES CORPORATION (US) 2023-10-19 WO disclosed
WO-2023135397-A1 PROCESS FOR THE PREPARATION OF ANTIBODY-DRUG CONJUGATES MC SAF (FR) 2023-07-20 WO disclosed
WO-2023131219-A1 CONJUGATES, COMPOSITIONS AND METHODS OF USE VIRTUOSO BINCO, INC. (US) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381321-A1 CAMPTOTHECIN CONJUGATES DCLRE1A, TOP2A, PAICS RXFP1 4627/4885TDP1 741/4885ALDH1A1 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.